StockWatch
·

ALBERT DAVID LTD.-$

BSE: 524075

P/L Snapshot

Q1 FY27 · standalone

vs Q4 FY26·vs Q1 FY26
Revenue
129.30
+111.9%+39.6%
Expenditure
93.50
+8.4%+11.1%
Net Profit
32.00
+249.3%+303.1%
OPM %
10.49%
+7.28pp+25.59pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-39.527.2053.93100.66147.39Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Price Chart
Reports

Albert David Q1 FY27: standalone PAT surges 303% YoY to ₹32 Cr as margins expand sharply

pharmaceuticals · margin expansion · tax credit

ResultsQ1 FY2706 Aug 20263 minPharma & Healthcare
Latest
Board Meeting6 Aug, 3:38 pm

Albert David Q1 FY27: standalone PAT surges 303% YoY to ₹32 Cr as margins expand sharply

Albert David Limited's standalone Q1 FY27 (quarter ended June 30, 2026) results show revenue from operations up 43.6% YoY to ₹101.34 Cr (₹70.57 Cr in Q1 FY26), and net profit up 303% YoY to ₹32.00 Cr (₹7.94 Cr in Q1 FY26) — a sharp jump in profitability. Net profit margin expanded to 24.75% from 8.57% a year ago. Sequentially the company swung from a ₹21.43 Cr net loss in Q4 FY26 to this quarter's ₹32.00 Cr profit, but Q4 figures are the balancing residual between audited full-year numbers and the nine-month run-rate (per the filing's own note), so that QoQ swing is less informative than the YoY trend, which is the primary read here. The margin expansion was driven almost entirely by expense discipline against a strong topline: total expenses rose just 11.1% YoY (₹93.50 Cr vs ₹84.16 Cr) even as revenue grew 43.6%, with employee benefit costs actually declining YoY (₹25.55 Cr vs ₹28.43 Cr). Reported PAT was also lifted by a ₹2.35 Cr prior-year tax credit booked this quarter; excluding it, adjusted PAT growth is still a strong ~274% YoY (₹29.65 Cr adjusted vs ₹7.94 Cr), confirming the growth is largely operational rather than a tax-line artefact. Pre-tax profit (before exceptional items, of which there were none) came in at ₹35.79 Cr against ₹8.44 Cr a year ago. Albert David carries no visible analyst/street coverage — a web search for Q1 FY27 previews or consensus estimates on the company returned no results, consistent with its small-cap, standalone-only profile. There is also no prior management guidance on record and none surfaced in search, so vsGuidance is unknown rather than a miss. The result comes alongside a leadership transition: Amit Mahla, appointed Whole-time Director & CEO on June 19, 2026, signs this filing, following a cluster-head resignation on July 4, 2026 — the new CEO's first quarterly print shows a clear margin improvement, though one quarter is too early to attribute it to the leadership change. Basic EPS (not annualised) was ₹56.07 versus ₹13.91 a year ago and -₹37.56 in Q4 FY26. With no exceptional items and the tax-credit effect isolated, the quarter sets up a watch on whether the ~43.6% revenue growth pace and the lower employee-cost run-rate hold into Q2 FY27, and whether the effective tax rate normalizes toward the ~17% implied by this quarter's core (non-credit) tax expense.

6 Aug 2026, 03:38 pm

Corporate Events

Board MeetingALBERTDAVD
2026
6Aug

Board Meeting

The 87th Annual General Meeting (AGM) of Members of the Comp…

BSE Filing
DividendALBERTDAVD
2026
30Jul

₹5 / share

BSE Filing
Board MeetingALBERTDAVD
2026
19Jun

Board Meeting

The Board of Directors approved the appointment of Mr. Amit…

BSE Filing
Board MeetingALBERTDAVD
2026
11Feb

Board Meeting

To consider, approve and take on record the Unaudited Financ…

BSE Filing
Board MeetingALBERTDAVD
2024
13May

Board Meeting

Consider and approve the Audited Financial Results

BSE Filing
Board MeetingALBERTDAVD
2024
5Feb

Board Meeting

Consider and approve Un-audited financial results for the Qu…

BSE Filing
Board MeetingALBERTDAVD
2023
9Nov

Board Meeting

Consider and approve the Unaudited Financial Results of the …

BSE Filing
Board MeetingALBERTDAVD
2023
10Aug

Board Meeting

Consider and approve the Unaudited Financial Results of the …

BSE Filing